Outcomes comparing older HL patients with younger patients. (A) The 3- and 5-year failure-free survival for patients aged ≥60 years was 56% and 48%, respectively, compared with 76% and 74%, respectively, for patients aged <60 years (P = .002). (B) The 3- and 5-year OS for patients aged ≥60 years was 70% and 58%, respectively, compared with 93% and 90%, respectively, for patients aged <60 years (P < .0001). (C) The 2- and 5-year time-to-progression (TTP) for patients aged ≥60 years was 80% and 68%, respectively, compared with 81% and 78%, respectively, for patients aged <60 years (P = 0.37). (D) The rates of progression were determined with competing risk analysis, because death without progression is a competing risk for disease progression. The incidence rates of progression, including competing risks for patients aged ≥60 years, at 2 and 5 years were 19% and 30%, respectively, compared with 19% and 23%, respectively, for patients aged <60 years (P = .30); however, the incidence rates of death without progression for patients aged ≥60 years at 2 and 5 years were 13% and 22%, respectively, compared with 2% and 9%, respectively, for patients aged <60 years (P ≤ .0001). Reprinted with permission from Evens et al.¹⁰